The novel VAT-DHF score predicted atrial fibrillation recurrence after catheter ablation with an AUC of 0.869 (95% CI 0.802-0.936; p < 0.0001), outperforming APPLE and CHA2DS2-VASc scores.
Cohort (n=263)
Does the VAT-DHF score accurately predict atrial fibrillation recurrence in patients undergoing catheter ablation?
The novel VAT-DHF score demonstrates high predictive accuracy for atrial fibrillation recurrence following catheter ablation, outperforming existing scores like APPLE and CHA2DS2-VASc.
Effect estimate: AUC 0.869 (95% CI 0.802-0.936)
p-value: p=< 0.0001
Introduction: Catheter ablation (CA) for atrial fibrillation (AF) has been proven to have the highest efficacy in maintaining sinus rhythm. Several studies have proposed different scores for predicting post-procedural success, but most have not been validated in prospective cohorts. Further research is required to determine the optimal formulae. Purpose: This study aimed to identify independent predictors of AF recurrence after CA and develop a composite score. Methods: Consecutive patients with persistent and paroxysmal AF who underwent CA were retrospectively analyzed. The independent predictors of recurrence were used to create a new predictive score. Results: The cohort included 263 patients with a follow-up of 37.6 ± 23.4 months. Persistent AF, f-waves < 0.1 mV, indexed left atrium volume, the presence of type 2 diabetes, and smaller height were independent predictors of recurrence and were used to create a new scoring model, VAT-DHF (V = Volume, AT = AF Type, D = Diabetes, H = Height, F = f waves). The ROC curve for this new score showed an AUC of 0.869, p < 0.0001, 95% CI 0.802–0.936, while those for APPLE and CHA2DS2-VASc showed an AUC of 0.765, 95% CI 0.637–0.893 and an AUC of 0.655, 95% CI 0.580–0.730, respectively. Patients who had a VAT-DHF score between 0 and 3.25, 3.25 and 6, and ≥6, had success rates of 95.7%, 76.3%, and 25% (p < 0.0001), respectively. Conclusions: The novel VAT-DHF score is easy to calculate and may be a useful clinical tool for identifying patients with a low, intermediate, or high risk of AF recurrence after CA.
Năstasă et al. (Fri,) conducted a cohort in Atrial fibrillation (n=263). VAT-DHF score vs. APPLE and CHA2DS2-VASc scores was evaluated on Atrial fibrillation recurrence after catheter ablation (AUC 0.869, 95% CI 0.802-0.936, p=< 0.0001). The novel VAT-DHF score predicted atrial fibrillation recurrence after catheter ablation with an AUC of 0.869 (95% CI 0.802-0.936; p < 0.0001), outperforming APPLE and CHA2DS2-VASc scores.